BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Mixed Q3 2025 Results with Revenue Growth but Earnings Miss

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported third-quarter 2025 financial results that presented investors with a mixed performance picture, characterized by revenue resilience but significant earnings pressure. The company's latest earnings release triggered modest market movement as traders weighed solid top-line execution against substantial bottom-line underperformance.

Quarterly Financial Performance

The biotechnology company delivered $776.1 million in third-quarter revenue, representing 4.1% year-over-year growth. While this figure fell slightly short of analyst expectations, it demonstrated consistent demand for the company's rare disease portfolio. However, the earnings picture proved more challenging, with non-GAAP EPS of $0.12 falling significantly below consensus estimates.

Key financial metrics versus expectations:

• Revenue: $776.1 million actual versus $799.2 million estimated
• Non-GAAP EPS: $0.12 actual versus $0.47 estimated
• Year-over-year revenue growth: 4.1%

Market Reaction and Stock Performance

Trading activity following the earnings release reflected investor uncertainty in interpreting these mixed results. The stock showed moderate positive movement in after-hours trading, suggesting some investors focused on the company's maintained full-year guidance rather than the quarterly earnings miss. Recent performance trends indicate cautious optimism among market participants.

Recent price movements:

• After-market performance: +1.29%
• One-week performance: +2.23%
• Two-week performance: +4.13%
• One-month performance: +1.17%

Corporate Update and Strategic Highlights

BioMarin's corporate update highlighted several positive developments despite the earnings shortfall. The company raised its full-year 2025 total revenue guidance at the midpoint while reaffirming its specific outlook for VOXZOGO. Year-to-date performance metrics revealed stronger underlying business trends than the quarterly numbers alone might suggest.

Notable corporate developments:

• Year-to-date total revenues increased 11% year-over-year
• PALYNZIQ and VOXZOGO demonstrated revenue growth exceeding 20%
• Full-year revenue guidance raised to $3.18 billion at the midpoint
• VOXZOGO full-year outlook reaffirmed

Forward Guidance and Analyst Expectations

The company's updated full-year revenue guidance of $3.18 billion at the midpoint positions it slightly below analyst expectations of $3.24 billion for 2025 sales. For the upcoming fourth quarter, analysts project revenue of $837.4 million, which the company will need to exceed to demonstrate accelerating growth momentum.

Investment Considerations

BioMarin's third-quarter results highlight the ongoing transition within its product portfolio, with established products facing competitive pressures while newer therapies like VOXZOGO show robust growth. The significant earnings miss raises questions about margin management and cost control, particularly as the company invests in commercializing newer therapies and advancing its clinical pipeline.

The market's relatively muted reaction suggests investors are weighing near-term earnings pressure against long-term growth potential from the company's rare disease franchise. The maintained guidance for VOXZOGO indicates management confidence in this growth driver, while the raised overall revenue outlook signals improving visibility across the product portfolio.

For detailed earnings estimates and future projections, view comprehensive data on Chartmill.

Disclaimer: This article provides financial analysis for informational purposes only and does not constitute investment advice, recommendation, or endorsement of any security. Investors should conduct their own research and consult with financial advisors before making investment decisions.